Gnosis Health, a digital healthcare startup building a healthcare assistant for Parkinson’s disease, has raised £1.1m in funding led by SFC Capital with participation from Northstar Ventures and Innovate UK. The funds will enable Gnosis Health to complete its North East NHS pilots, scale the engineering team, and prepare MAXine for its commercial debut.
A spinout of the universities of Newcastle and Plymouth, Gnosis Health is developing MAXine to improve the management of Parkinson’s disease. The assistant integrates data from wearables, patient reported outcomes and behavioural patterns to provide real time insights to patients and clinicians. By offering continuous, adaptive monitoring, MAXine supports self-management and improves communication between patients and care teams.
More than 153,000 people in the UK are affected by Parkinson’s disease, while people living with the condition typically receive only 30 minutes of clinician time per year. Symptoms fluctuate and require consistent monitoring, but existing approaches rely largely on questionnaires or infrequent clinical observation. MAXine captures symptom changes throughout the day and generates actionable insights.
Pilot studies have shown strong patient engagement, alongside a potential 25% reduction in patient care costs. The global AI healthcare market is expected to reach around $102 billion by 2028. MAXine is designed to work with any commercial wearable device and uses bespoke explainable AI models, a federated-learning approach and a focus on clinical specificity.
Founded by Prof. Edward Meinert and Jerrell Schivers, Gnosis Health brings together experience in software engineering, AI model development and clinical research. The IP is backed by more than £2 million in competitive grant funding. Gnosis Health is supported by Parkinson’s charities including Parkinson’s UK and Cure Parkinson’s.
Our universities are renowned for producing spinout companies that have global potential. Gnosis Health is tackling one of the most pressing challenges in chronic disease management. MAXine represents a step change in remote monitoring for Parkinson’s, combining clinical rigour with cutting edge AI to deliver meaningful value to patients and care teams alike. We’re proud to support a company with such clear potential to improve quality of life and reshape how chronic conditions are managed across the NHS and beyond.
Northstar Ventures played a pivotal role in the early development of Gnosis Health, providing both strategic advice and steadfast support at a stage when the company was still taking shape. That early partnership helped lay the foundations for what has now become a successful spinout and commercial launch. We would not be where we are today without Northstar’s belief in the vision from the outset.
